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Abstract
Several objectives underlie the current article. First, to review historical diagnostic
issues and clinical strategies for treating SE-AN. Second, to provide an overview of
recent evidence informed strategies and clinical innovations for the treatment of
SE-AN. Third, based on the authors' collective clinical and research experience, we
offer eight observations that we believe capture the current clinical experience of
patients with SE-AN. Some of these observations represent empirically testable
hypotheses, but all are designed to generate a meaningful discussion about the treat-
ment of this group of individuals with eating disorders. Finally, we hope to call clini-
cians, scientists, professional organizations, advocates, and policy makers to action to
attend to critical issues related to the care of individuals with SE-AN. We believe that
an international discussion could clarify areas of need for these patients and identify
opportunities for clinical innovation that would enhance the lives of individuals with
SE-AN and their families.
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Anorexia nervosa (AN) is most common in girls and young women with
a lifetime prevalence in women of up to 2–4% (Galmiche, Dechelotte,
Lambert, & Tavolacci, 2019; Keski-Rahkonen & Mustelin, 2016; Smink,
van Hoeken, & Hoek, 2013). The highest prevalence of AN has been
reported in Europe, North America, and Australasia with increasing
reports from Asia (Hoek, 2016; Nakai, Nin, & Noma, 2014; Thomas,
Lee, & Becker, 2016; Tong et al., 2014). AN is a very rare disorder in
Africa and Latin America, while other eating disorders are common on
these continents (Kolar, Rodriguez, Chams, & Hoek, 2016; van Hoeken,
Burns, & Hoek, 2016). AN has a crude mortality rate of 5% per decade
and a standardized mortality ratio of around 6 (Arcelus, Mitchell,
Wales, & Nielsen, 2011; Fichter & Quadflieg, 2016; Smink et al., 2013).
First-line treatments for AN typically consist of weight restoration
and eating disorder focused psychotherapies, with family-based inter-
ventions for children and adolescents (Fisher, Skocic, Rutherford, &
Hetrick, 2019) and various individual psychotherapies for adults
(Brockmeyer, Friederich, & Schmidt, 2018; van den Berg et al., 2019;
Zeeck et al., 2018). Antidepressant or antipsychotic medications have
little or no effect and/or have low acceptability (Attia et al., 2019;
Himmerich & Treasure, 2018). Inpatient and residential treatment is
costly and reserved for those with the most severe form of the illness
in many countries. Across the age range, and with best available treat-
ments, recovery rates at 1–2 year follow-up range from 13 to 50% in
recent trials (Brockmeyer et al., 2018; Fichter, Quadflieg, Crosby, &
Koch, 2017). Up to 20–30% of AN patients develop a persistent and
sometimes life-long form of the illness, often punctuated by a series
of unsuccessful treatments (Dobrescu et al., 2019; Eddy et al., 2017;
Herpertz-Dahlmann et al., 2018; Støving, Andries, Brixen, Bilenberg, &
Hørder, 2011). This group of patients has come to be characterized as
having severe and enduring anorexia nervosa (SE-AN) (Broomfield,
Stedal, Touyz, & Rhodes, 2017; Hay & Touyz, 2015).
Our overall intention for this article is to provide an informative
update on SE-AN and not a systematic review. We reviewed the most
important recent articles related to SE-AN using PubMED, PsycInfo,
Ovid database, and Google Scholar. Our specific aims were to:
(a) briefly review historical diagnostic issues and clinical strategies for
treating SE-AN, (b) provide an overview of recent evidence-informed
strategies and clinical innovations for the treatment of SE-AN, and
(c) offer eight observations by the authors that are thought to capture
the current clinical experience of patients with SE-AN. Finally, we
conclude with a summary of our thoughts and concerns about the sta-
tus of SE-AN patients in our field and strategies to enhance care.
1 | ISSUES RELATED TO DESCRIBING AND
DEFINING ENDURING FORMS OF ANOREXIA
NERVOSA
Although AN is conceptualized as a disorder that typically lasts several
years, considerable interest has emerged in describing and understand-
ing clinical presentations that are enduring and often challenging to treat
(Touyz, Le Grange, Lacey, & Hay, 2016). In a meta-analysis, Broomfield
et al. (2017) emphasized two different descriptive components of this
body of work: (a) different ways in which authors and clinicians have his-
torically referred to or “labeled” this presentation, and (b) varying efforts
to more formally define and classify enduring forms of AN.
Broomfield et al. (2017) delineate numerous labels that have been
applied to enduring forms of AN. For example, terms including
“chronic,” “severe,” “enduring,” “treatment resistant,” “recalcitrant,” and
“long-standing” have all been used to characterize this population. Clini-
cians often express concern that these labels connote different
meanings, which may influence clinicians' perspectives on treatment, as
well as patients' narratives about their illness and chances of recovery.
For example, the labels of “chronic” and “treatment resistant” both may
influence clinicians' views of a patient's treatability or willingness to col-
laborate in their treatment. Broomfield et al. (2017) indicate that while
the label “chronic” is the most common term used to describe this
patient population, other terms are emerging that may be less focused
on an individual's treatability, such as “severe and enduring,”
“longstanding,” and other variations of severity and duration labels.
The idea of creating a classification system for enduring variations
of AN has also been discussed and our article builds on the pioneering
work by the Australians Hay and Touyz (Hay & Touyz, 2015; Hay &
Touyz, 2018; Hay, Touyz, & Sud, 2012) and other relevant papers
(Ciao, Accurso, & Wonderlich, 2016; Wonderlich et al., 2012). Gener-
ally efforts to classify this population integrate three or four dimen-
sions or variables. Examples of dimensions include duration of the
illness, severity of the illness, evidence of unsuccessful treatments,
and occasionally, patient age. Each of these dimensions poses difficul-
ties for classification. For example, duration of the illness varies signif-
icantly across different definitions and has ranged from 3 to 10 years
(Ciao et al., 2016). Similarly, unsuccessful treatment experience is
rarely operationalized and is hard to define. Was the unsuccessful
intervention an evidence-based treatment for eating disorders, any
eating disorder treatment, any psychiatric treatment, or simply any
type of clinical management? Also, the issue of patient age is impor-
tant to consider, but difficult to place into formal classification.
Whether a relatively young individual with AN (e.g., 18–22 years of
age) should be labeled as “chronic” has caused considerable concern
because of the labeling implications and possible impact on treatment
(i.e., premature movement into a harm reduction model of care). Given
the evidence that some individuals with enduring forms of the disor-
der ultimately do recover after decades with the illness (Eddy
et al., 2017), the age and developmental status of the patient needs to
be carefully considered when making treatment decisions.
Importantly, Hay and Touyz (2018) have recently provided clarifi-
cation of the classification of SE-AN individuals with a proposed set
of empirically testable criteria which includes a specific criterion for
duration (i.e., greater than 3 years) that is similar to definitions of
other enduring psychiatric disorders (e.g., psychosis; Ruggeri, Leese,
Thornicroft, Bisoffi, & Tansella, 2000) and operational criteria for
unsuccessful treatments (i.e., exposure to at least two evidence-based
treatments appropriately delivered). Their proposed classification
criteria are included in Table 1 and it should be noted that the authors
TABLE 1 Proposed criteria for “Severe and Enduring Anorexia
Nervosa” (Hay & Touyz, 2018)
(1) A persistent state of dietary restriction, underweight, and
overvaluation of weight/shape with functional impairment
(2) Duration of >3 years of anorexia nervosa; and
(3) Exposure to at least two evidence-based treatments appropriately
delivered together with a diagnostic assessment and formulation
that incorporates an assessment of the person's eating disorder
health literacy and stage of change
themselves recognize limitations in these criteria and strongly support
empirical tests to clarify the best defining features of SE-AN (Hay &
Touyz, 2018). Although there may be some debate about whether
classification criteria and clear definitions are needed for SE-AN, it is
worth noting that a recent practice guideline has been developed that
does, in fact, propose alternative treatment strategies for individuals
meeting diagnostic criteria for SE-AN (Hay et al., 2016). This develop-
ment in a professional treatment guideline has significant implications
for individuals with AN in general, and in particular for those meeting
criteria for SE-AN. Given the clinical implications of such a taxonomy,
efforts to enhance definitional clarity, along with empirical tests of the
classification criteria, are encouraged.
2 | CLINICAL RECOMMENDATIONS AND
TECHNIQUES FOR TREATING SE-AN
(1980–2010)
In the 1980s, clinicians who treated eating disorders began to recognize
the complexity of SE-AN and offered explicit recommendations regard-
ing the treatment of this subgroup of individuals with eating disorders.
A series of papers and books emerged that outlined strategies for
SE-AN treatment, which differed in meaningful ways from existing eat-
ing disorder treatments. These publications (e.g., Goldner, 1989; Ham-
burg, Herzog, Brotman, & Stasior, 1989; Robinson, 2009;
Strober, 2004; Yager, 1992) delineated a collection of clinical ideas that
the authors believed should be considered and implemented in the
treatment of SE-AN. The treatment approaches were neither evidence-
based nor rigorously tested in robust scientific studies, but were largely
based on theoretical conceptualizations and clinical experience. The fol-
lowing themes or ideas were highlighted across this literature. First, cli-
nicians were generally encouraged to tolerate and manage extreme
ambivalence or resistance to weight regain in SE-AN patients, as
opposed to focusing primarily, or solely on weight gain (Goldner, 1989;
Hamburg et al., 1989; Yager, 1992). Second, patients with SE-AN were
thought to be best treated in the context of a comprehensive, multi-
disciplinary team that could provide varying levels of care (Hamburg
et al., 1989; Strober, 2004; Yager, 1992). Some clinicians also rec-
ommended a treatment approach that might best be considered psychi-
atric rehabilitation, similar to that seen in other serious psychiatric
disorders, such as schizophrenia (Robinson, 2009). Third, the authors
clearly encouraged modification of treatment goals in SE-AN relative to
more acute cases of AN. Rather than emphasizing meal planning or sig-
nificant increases in food consumption, along with weight gain, these
authors generally relied on defining alternative treatment targets
(e.g., quality of life, social adjustment). Fourth, some authors
(Goldner, 1989; Yager, 1992) encouraged clinicians to carefully consider
the judicious use of legal interventions in SE-AN, particularly regarding
involuntary commitment, legal incompetency, and patients below the
age of majority. Finally, there was a general suggestion to include carers
in the treatment of SE-AN patients. Family inclusion could allow a vari-
ety of meaningful interventions ranging from careful historical reviews
of past treatment history, psychoeducation about eating disorders,
families coming to terms with the severity of the illness, and general
support of the family.
In 2012, Wonderlich and colleagues synthesized this information
and highlighted the lack of empirical evidence supporting any treat-
ment for this group of patients. These authors noted the challenging
and persistent difficulties often encountered in SE-AN treatment
including serious psychiatric and medical emergencies, and repeated
cycles of significant behavioral change followed by serious relapse.
Thus, in 2012, questions were clearly emerging regarding the best
approaches to treating patients with SE-AN and concerns that these
patients were often receiving a relatively unfocused intervention with
uncertain intensity, duration, goals, and a lack of integration across
different levels of care. Around this time, empirical studies on course
of SE-AN were beginning to be considered (Eddy et al., 2017) and
importantly, a randomized, controlled trial was being conducted in
Australia that focused on SE-AN (Touyz et al., 2013). A summary of
empirical studies on clinical course and treatment of SE-AN will be
provided next.
2.1 | Empirical studies on clinical course
and treatment of SE-AN
It has been widely assumed in the eating disorder field that long dura-
tion of illness predicts poor prognosis and treatment outcome in
AN. However, studies on the prognostic effects of illness duration have
produced surprisingly mixed results—some indicating an association
with unfavorable treatment response (Steinhausen, 2002; Von Holle
et al., 2008; Wild et al., 2016) and others suggesting negligible effects
(Calugi, El Ghoch, & Dalle Grave, 2017; Raykos, Erceg-Hurn, McEvoy,
Fursland, & Waller, 2018). It is worth noting that these studies vary sig-
nificantly in terms of their definitions of SE-AN with some simply exam-
ining the effects of duration and others specifying categorical
definitions of SE-AN. Furthermore, long-term follow-up studies (which
now span intervals exceeding 30 years) reveal an illness trajectory char-
acterized by progressively larger proportions of people recovering from
AN over the long term (Dobrescu et al., 2019; Eddy et al., 2017; Keel &
Brown, 2010; Nilsson & Hägglöf, 2005). For example, although it has
been known that around 30% of AN patients recover in the first decade
of the illness, recent data suggest that approximately another third of
AN patients followed through a second decade will also recover (Eddy
et al., 2017). Such observations challenge the ominous belief that indi-
viduals with SE-AN are “beyond help.” Studies examining the specific
question of treatment responsiveness in individuals with SE-AN lend
even more direct support to the idea that many SE-AN patients may
indeed benefit from structured, short-term treatments.
2.2 | Treatment studies of SE-AN
In 2012, prior to the availability of any randomized controlled trials
(RCTs) evaluating specific treatments for SE-AN, Hay and colleagues
reviewed 11 then-available RCTs involving at least some participants
with SE-AN (Hay et al., 2012). Based on their review, these authors
concluded that specialist treatment yielded better results than did
nonspecialist “treatment as usual” for patients with SE-AN. Their
review also indicated that, in this population, CBT adapted for AN
(CBT-AN) might reduce relapse, and that adjunctive olanzapine might
enhance weight gain and symptom reduction.
Since 2012, there has been only one formal RCT addressing psy-
chotherapeutic treatment of SE-AN, conducted in 63 individuals with
AN of at least 7 years duration (Touyz et al., 2013). The study com-
pared the efficacy of 30 sessions of an adapted form of CBT-AN to
that of an adapted form of Specialist Supportive Clinical Management
for AN (SSCM-AN), with adjustments in both treatments prioritizing
enhanced quality of life and harm reduction, rather than weight-gain
and symptom-reduction. Both treatments yielded improvements in
quality of life and, unexpectedly, produced modest weight gains and
reductions of eating symptoms for up to 1 year post-treatment. Fur-
thermore, the rate of attrition from both treatments was very low—
15% overall. In other words, the adapted treatments led to weight
gains and improved AN symptoms. A secondary analysis of the same
data found that younger age, lower chronicity of illness, nonpurging
illness type, and better social adjustment at baseline predicted better
outcomes (Le Grange et al., 2014). Yet another secondary analysis
showed that good therapeutic alliance predicted positive response on
both eating-specific and generalized symptoms (Stiles-Shields
et al., 2013). Together, findings from this study demonstrate that
SE-AN can be treated, and point to the importance of designing
treatments that optimize patient engagement.
Although not RCTs, several studies have examined the value of
what is probably the best-established psychological treatment for
EDs—namely CBT-E (Fairburn et al., 2009) in the treatment of SE-AN.
The first, by Calugi and colleagues (Calugi et al., 2017), compared out-
comes in 66 adult patients with AN who were subdivided into groups
with illness duration less than, or greater than, 7 years. All participants
received CBT-E as a component of inpatient treatment. Results
showed that both groups displayed similar increases in body mass
index (BMI) and improvements in eating symptoms and general psy-
chopathology. After discharge, both groups showed similar rates
(upwards of 40% for completers) of good outcome (BMI greater than
18.5 kg/m2) and 12-month “minimal ED symptom” rates were 32 and
33%, respectively. In a related vein, Raykos et al. (2018) examined
associations between effects of illness severity or duration upon out-
come in outpatient CBT-E. In a sample of 134 AN patients, it was
observed that neither illness severity nor duration predicted
outcome—such that patients with more severe or long-standing ill-
nesses did as well in CBT-E as did other patients. Although the latter
study was limited by attrition from follow-up, an implication is that
chronicity of illness may not be as detrimental to outcome as has been
thought.
Another study involved the Maudsley Model of Anorexia Nervosa
Treatment for Adults (MANTRA), which is a manual-based, multimodal
outpatient treatment for adults with AN (Schmidt et al., 2015;
Schmidt et al., 2016; Schmidt & Treasure, 2006) recommended by
NICE as a first line treatment (Hilbert, Hoek, & Schmidt, 2017;
National Institute for Health and Care Excellence, 2017). Although
there have been no RCTs specifically testing MANTRA as a treatment
for SE-AN, Wade, Treasure, and Schmidt (2011) documented a study
of 33 outpatients treated with MANTRA in which completers had a
mean illness duration of over 8 years. Improvements in BMI and eat-
ing symptoms were reported at 12-month follow-up and, notably,
duration of illness was not a significant predictor of quality of
outcome.
In another study, secondary analysis of a multisite clinical trial
of adult outpatients with AN (N = 187) provide a contrast to the
findings just-reviewed (Ambwani et al., 2020). Trial participants all
had been offered NICE-recommended psychotherapies augmented
by a short, digital treatment (Cardi et al., 2019). Patients were
grouped into two categories: those in an “early stage” (illness dura-
tion <3 years; n = 60) and those representing a “severe and endur-
ing” stage (SE-AN; n = 41), defined by level of distress
(Depression, Anxiety and Stress Scale; DASS-total ≥ 60) and illness
duration (≥7 years). Baseline comparisons between “early stage”
versus SE-AN patients indicated poorer work/social adjustment and
higher ED symptomatology among SE-AN patients. Comparisons
between assessments conducted at baseline and then after
12 months indicated higher rates of improvement on work/social
adjustment among “early stage” patients. Of note, SE-AN patients
had higher rates of accessing intensive services (inpatient or day
treatment) than did those with “early stage” illness.
3 | CONTEMPORARY CLINICAL
INNOVATIONS IN SE-AN
3.1 | Building the evidence base
Novel behavioral, pharmacologic, and service delivery approaches to
treatment are being developed and tested to address illness persis-
tence or chronicity. Some of these attempt to impact broader issues,
such as harm reduction or improvements in quality of life. Further-
more, some emerging interventions are being proposed specifically for
SE-AN on theoretical grounds (i.e., as targeting possible illness mainte-
nance factors) whereas others are being proposed for SE-AN, but not
in more acute AN, because they are very resource intensive in terms
of service delivery costs and personnel time required, and may have
to be reserved for treatment of the most severe cases.
3.1.1 | Behavioral treatments
A range of behavioral interventions that have emerged from studies
of acute AN, including altering fear learning processes via exposure or
reconsolidation approaches (Murray et al., 2018) or reversing anorexic
habits in relation to maladaptive food choices and more general habit-
proneness (Steinglass et al., 2018), are being discussed as potentially
useful for SE-AN. To the best of our knowledge, these have yet to be
specifically tested in patients with SE-AN.
Cognitive inflexibility and excessive detail focus have been exten-
sively studied in AN (Smith, Mason, Johnson, Lavender, &
Wonderlich, 2018) and are thought to be associated with more endur-
ing illness (Lang, Stahl, Espie, Treasure, & Tchanturia, 2014). One RCT
involving 82 adult in-patients with a severe and/or enduring illness
AN spectrum illness, studied effects of a 10-session cognitive remedi-
ation therapy (CRT) that used a range of cognitive exercises to
improve cognitive flexibility and information processing (Dingemans
et al., 2014). All patients received about 30 hr per week of compre-
hensive inpatient care with multiple treatment components, and half
of these patients also received CRT as an adjunct to their treatment.
Outcome measures assessed set-shifting, central coherence, ED
symptoms, general psychopathology, motivation, quality of life, and
self-esteem. Although the CRT adjunct did not promote more rapid
weight gain, patients who received adjunctive CRT showed larger
improvements on ED-related quality of life at the end of treatment
and on ED symptoms at 6-month follow-up. However, a more recent
trial by the same group comparing CRT with an active control therapy,
both added to AN treatment as usual, did not find CRT to be superior
to active control treatment (van Passel et al., 2020).
3.1.2 | Pharmacologic interventions
A range of novel medications is being considered for reduction of
symptoms in SE-AN. For example, evidence has emerged demonstrat-
ing a role of oxytocin in the AN disease process. The operative mech-
anism may be related to homeostatic and reward-related processes
involved in the regulation of food intake, but also via pathways involv-
ing attachment experiences and social cognition, all of which are
impaired in AN (Giel, Zipfel, & Hallschmid, 2018; Thaler et al., 2020).
Likewise, use of ketamine preparations to treat the depression
that commonly accompanies SE-AN is being discussed (Price &
Duman, 2019). Neither oxytocin nor ketamine have to date been
trialed in SE-AN.
One small cross-over RCT tested the adjunctive use of the
appetite-enhancing cannabinoid agonist, dronabinol, in 25 women
with AN of at least 5 years duration. Participants were randomized to
treatment with either dronabinol-then-placebo or placebo-then-
dronabinol, added to treatment as usual (Andries, Frystyk, Flyvbjerg, &
Støving, 2014). During dronabinol treatment, participants gained
0.73 kg more, on average, than during placebo. In other words, the
active drug induced small, but significant increases in weight gain
without adverse events.
3.1.3 | Brain stimulation interventions
Neurobiological models of AN tend to focus on an altered balance
between neural mechanisms related to reward and those related to
cognitive control/inhibitory systems (Dalton et al., 2018). These
models have motivated the development of neurostimulation tech-
niques in EDs, both as illness probes and as potential treatment
modalities. Neurostimulation has been defined as “any intervention
intended to alter nervous system function by using energy fields
such as electricity, magnetism, or both” (Dalton, Campbell, &
Schmidt, 2017). Contemporary therapeutic neurostimulation methods
use a range of devices to enhance or suppress brain and neuronal
activity for the treatment of disease, including the noninvasive
methods of repetitive transcranial magnetic stimulation (rTMS) and
transcranial direct current stimulation (tDCS) and the surgical method
of deep brain stimulation (DBS).
Several single case studies, case series, and proof-of-concept
RCTs of noninvasive brain stimulation methods (rTMS, tDCS) in AN
have shown promise, improving ED symptoms, mood and decision
making and are safe and well-tolerated in AN (McClelland et al., 2016;
McClelland, Kekic, Campbell, & Schmidt, 2016; Van den Eynde,
Guillaume, Broadbent, Campbell, & Schmidt, 2013). Recently, a feasi-
bility sham-controlled double blind randomized controlled trial (RCT)
of 20 sessions of high frequency rTMS to the left DLPFC was con-
ducted, in 34 SE-AN patients (17/group) (Dalton et al., 2018). Treat-
ment (vs. sham) effect sizes (Cohen's d) of symptom change (baseline
to 4 months) were small for BMI (d = 0.2) and ED symptoms (d = 0.1),
medium for quality of life and moderate to large (ds = 0.61–1.0) for
mood. In an 18-month open follow-up, improvements in mood were
largely maintained and 45.5% of the original real rTMS group were
weight recovered (BMI > 18.5 kg/m2) versus only 9.0% of the original
sham group (Dalton et al., submitted). The delay in BMI improvement
may be due to the delayed effects of TMS on neuroplasticity (Cirillo
et al., 2017).
DBS involves the surgical implantation of electrodes in targeted
brain structures so as to allow for controlled, local electrical stimula-
tion. The procedure has been studied as a treatment option for severe
and refractory AN by several different groups, using different stimula-
tion targets, including the bed nucleus of the stria terminalis, the sub-
callosal cingulate, the nucleus accumbens, or the ventral/capsule/
ventral striatum (Sobstyl, Stapinska-Syniec, Sokol-Szawlowska, &
Kupryjaniuk, 2019). The largest series to date included 16 patients
with chronic and treatment-refractory AN (Lipsman et al., 2017). Sub-
callosal cingulate DBS was associated with an average BMI increase
from 13.83 (SD 1.49) at pre-treatment to 17.34 after 12 months of
stimulation. DBS was also associated with significant improvements in
depression, anxiety, and affect regulation. These preliminary results
show that DBS may be a viable treatment option in SE-AN, although
several non-negligible adverse events were also reported.
3.2 | Innovation in clinical delivery systems
A range of other interventions has recently been developed to reduce
harms and improve quality of life in SE-AN. For instance, Munro
et al. (2014) reported on the effectiveness of an intensive treatment
for SE-AN, offered by an outpatient Anorexia Nervosa Intensive
Treatment Team. The treatment, which applied supportive care and
cognitive components, was associated with high patient and staff sat-
isfaction ratings, good medical safety outcomes, and low attrition over
a 3-year period. A similar outpatient approach, the Community Out-
reach Partnership Program (Williams, Dobney, & Geller, 2010) offered
treatment to patients in their communities using goals (set by patients
themselves) focused on symptom management, skill develop-
ment, and understanding benefits and risks of symptoms. After an
average of 25 months, 18 “chronic” patients (mean duration of ill-
ness = 15.23 years) showed significant improvements in eating symp-
toms and weight, but not quality of life. In a similar vein, Long,
Fitzgerald, and Hollin (2012) evaluated the effectiveness of a multi-
modal, multidisciplinary stepped-care approach (involving inpatient
and then outpatient care) for adults with AN who had been described
as showing severe symptoms and/or chronic lack of improvement in
outpatient treatment. The intervention involved a program of individ-
ual, group, and family-based interventions that allowed for the setting
of structured short-term goals, attention to leisure pursuits and com-
munity re-integration, and work with family members and partners.
Results showed 44% of the patients to be rated as “in remission” at a
4-year post-treatment follow-up, based on a criterion requiring
resumption of menses, BMI over 18, and relative absence of eating-
disordered attitudes and behaviors.
Finally, although quantitative outcome indices are pending, two
reports address a novel “self-admission” approach to treating SE-AN
(Strand, Bulik, von Hausswolff-Juhlin, & Gustafsson, 2017; Strand,
Gustafsson, Bulik, & von Hausswolff-Juhlin, 2017). In the program,
two beds on an adult inpatient ward are earmarked for self-admission
and self-discharge. Eligible patients must have undergone at least one
inpatient treatment during the past 3 years, and to have subsequently
been followed in the unit's outpatient or day-treatment services.
Patients are invited to complete a contract for self-admission. A quali-
tative content analysis of self-admission experiences of 16 AN
patients with a mean duration of illness of 15 years (range 3–42)
suggested that access to brief self-admissions increased feelings of
security, supported development of healthier behaviors, and helped
prevent needs for longer hospitalizations.
4 | OBSERVATIONS ABOUT THE NATURE
OF ACTUAL TREATMENT DELIVERED
TO SE-AN PATIENTS
Although the evidence base is growing and will eventually inform new
and efficacious treatments for individuals with SE-AN, we now turn
our attention to a topic that is more reflective of the current state of
affairs. We hope that we have effectively conveyed that there are a
significant number of individuals with AN who have a complex eating
disorder that is psychiatrically, medically, and socially extremely
impairing. Furthermore, empirically supported treatments for these
individuals are scarce, yet they represent a portion of our patient pop-
ulation that is in great need of care. In this section, we reflect on the
nature of treatments that individuals with SE-AN are actually receiv-
ing in 2020. Based on our clinical and research experience, we present
a list of observations that we believe capture the essence of these
patients' typical clinical experience. We acknowledge that these
observations reflect our perspective only, and may not accurately or
completely capture the current experience of all patients with SE-AN;
however, our intention is to offer these observations in an effort to
generate discussion about the nature of care generally provided to
individuals with SE-AN.
1. Regarding the nature of SE-AN treatment actually received, we
surmise that individuals with SE-AN are particularly likely to not
receive active eating disorder treatment. We anticipate the reasons
for this are many and include treatment burnout, loss of hope,
absence of community resources, absence of a treatment model
appropriate for their variant of illness, absence of financial
resources to pay for treatment, deep ambivalence about recovery,
and the hesitancy of clinicians to take on SE-AN cases because of
their complexity and potential fatality. Moreover, many individuals
with SE-AN may eschew treatment as they begin to feel as if AN is
integral to their identity and cannot imagine a life without the ill-
ness (Tierney & Fox, 2009).
2. For those who do receive treatment, extreme heterogeneity is likely
to exist with regard to treatment strategies for SE-AN. Given the
absence of a solid evidence base for this variant of AN, the mode of
treatment provided emerges primarily from expert opinion and may
be significantly affected by available resources in the community
both of which increase variability in treatment approach.
3. Protocols similar to those used in the Australian study (Touyz
et al., 2013) are unlikely to be broadly implemented in the treat-
ment of individuals with SE-AN for several reasons. First, few
treatment programs are adequately resourced to provide training,
supervision, outcome monitoring, and adherence measures while
providing evidence-based structured interventions to complex
patients. Second, many treatment centers may have relatively few
individuals with SE-AN in their active treatment census, meaning
that intensive training and adherence measures would not be cost-
effective. Third, clinicians may develop resistance to delivering
evidence-based or manualized interventions (von Ranson, Wal-
lace, & Stevenson, 2013). Fourth, across countries, and even within
treatment settings, clinician uncertainty about the best approach
to treating individuals with SE-AN, can lead to an approach that is
likely to include a nonspecialized, “eclectic” psychotherapy or
counseling, possibly accompanied by medical monitoring, and
pharmacotherapy with a multitude of treatment “targets.”
4. Although often not receiving specialist care for their eating disor-
der, individuals with SE-AN are particularly likely to be high uti-
lizers of healthcare (Stuhldreher et al., 2015). Emergency room
visits, medical hospitalizations, nonspecialist psychiatric hospitali-
zations, consultations with a variety of medical specialties can lead
to un-coordinated and expensive care. Also, we speculate that hos-
pitalizations of SE-AN patients are complicated because of the
myriad medical and psychiatric needs of these patients. Further-
more, iatrogenic problems would be more common in SE-AN than
in more acute, short-term AN cases, with more dangerous poly-
pharmacy, contradictory techniques or interventions, and differ-
ences of clinical opinion across providers.
5. For those SE-AN patients who do seek care on eating disorder inpa-
tient units, their unique needs may not be well met by programs that
are typically designed for younger and more acute cases (Bamford,
Mountford, & Geller, 2016). Moreover, the presence of SE-AN
patients on the unit can have complicated effects on the milieu—on
other patients, on parents and family members, and on staff. Youn-
ger patients can find the presence of SE-AN patients to be frighten-
ing (although for some it can be motivating for recovery). Parents
fear that their less severely ill children will learn dangerous behaviors
from the SE-AN patients and of course fear that their child might
also take on a chronic and severe course. Staff can become
demoralized when faced with caring for too many patients with SE-
AN without a clear blueprint for expectations of the hospitalization.
6. Clinicians are particularly likely to diagnose individuals with SE-AN
with other psychiatric disorders (e.g., mood disorders, anxiety dis-
orders, personality disorders, psychotic disorders) given the variety
of symptoms many of these patients experience. In the presence
of such a psychiatric comorbidity profile, care needs to be taken to
ensure accurate identification of the most significant disorders or
problems and prioritize treatment strategies accordingly. Our
observation is that in SE-AN, such careful diagnostic work and
associated treatment planning does not occur, routinely.
7. Patients with SE-AN are particularly likely to report having experi-
enced extreme or coercive efforts to increase body weight, typically
in higher levels of care, only to be followed by “weight relapse” and
a revolving door pattern of admission and discharge. Recent national
data from Denmark (Clausen, Larsen, Bulik, & Petersen, 2018) indi-
cates that nearly one in five AN patients has experienced involun-
tary treatment and a small number of AN patients (i.e., 2%)
experienced over 100 involuntary treatments. Repeat attempts at
refeeding that include limitations of privileges, intrusive observation,
forced bed rest, and involuntary treatment measures can become
unproductive and even traumatic for the patient, increasing the like-
lihood of them refusing future interventions.
8. Finally, in countries that rely heavily on private health insurance
(e.g., United States), individuals with SE-AN, especially those who
are receiving disability benefits, may not have private insurance, and
have a greater likelihood of relying on public insurance for health
care. Many facilities do not accept public insurance (Guarda,
Wonderlich, Kaye, & Attia, 2018), and we anticipate that SE-AN
patients are particularly likely to travel long distances to treatment
facilities that accept public insurance (if they can access them at all).
Of course, this also complicates effective discharge planning. Such
conditions result in treatments that are not well integrated across
providers and place a severe burden on patients and their families.
5 | SUMMARY AND FUTURE DIRECTIONS
The paucity of evidence-based treatments for SE-AN is striking and
underscores how much the field has neglected this most severe and
potentially fatal presentation of eating disorders. We see several fac-
tors that have contributed to this neglect, including professional
factors (training, education, support), political/financial (insurance,
access to care, research funding), social (stigma regarding eating disor-
ders), and geographical (absence of treatment facilities in close prox-
imity to patients).
As a first step we need data to clarify the nature and boundaries
of SE-AN to inform a possible diagnostic subcategory that can be con-
sidered for codification in subsequent versions of the DSM and ICD.
That said, as stated by many master clinicians who have written on
the topic, having SE-AN does not necessarily relegate one to a lifelong
illness, as many can, and do, recover—at least partially. Critical
research topics include how best to engage and retain people with
SE-AN in treatment; how best to support parents and loved ones who
are in caretaker roles; optimal tailoring of existing treatments or devel-
opment of new treatments for SE-AN; and a deeper understanding of
the specific biology of SE-AN and how it differs from more transient
AN cases in order to advance the evidence base and drug discovery.
As we discover more about the genetics and neurobiology of SE-AN,
and how it differs from more transient cases, our ability to predict
who might be at greatest risk of developing a chronic course may
improve and inform personalized medicine approaches designed to
obviate poor outcomes. Given that many centers only have small
numbers of SE-AN patients on their caseload, collaborative efforts
across several clinical research centers with complementary research
resources in the genetics and bio-behavioral processes underlying
SE-AN are required to achieve these scientific goals. Moreover
advancing SE-AN treatment outcome research by the careful applica-
tion of innovative adaptive designs may make better use of resources
and facilitate translation to clinical practice (Pallmann et al., 2018).
In parallel to these efforts, we recommend enhanced clinical train-
ing in delivering care to individuals with SE-AN. The goals of this train-
ing would be to increase clinician confidence in treating this population,
to guide the collaborative setting of achievable treatment goals, and to
develop support or supervision paradigms to obviate demoralization
and burnout. Furthermore, given the growing consideration of integrat-
ing palliative care or hospice into the treatment of some individuals with
SE-AN, we believe that discussions with ethicists/legal experts, clini-
cians, scientists and patient/carer organizations, are needed to better
conceptualize these approaches and develop protocols for clinicians,
patients, and families to ensure the best interests of the patient are pre-
served. Furthermore, staff who work in palliative care and hospice may
benefit significantly from educational activities regarding the nature and
treatment of eating disorders.
We strongly encourage professional organizations and funders to
acknowledge that the limited understanding of and paucity of treat-
ments for SE-AN represent a crisis in our field. Patients with SE-AN
report feeling marginalized and often distance themselves from treat-
ment centers that are ill-prepared to meet their needs. Alternatively,
SE-AN patients are also rejected by clinical centers due to limitations in
health insurance and funding support. SE-AN patients who are aged
18 or over, may exclude parents from clinical decision making even
when they are desperately ill and cognitively impaired, so privacy issues
must be addressed as part of this crisis. With this article as a spring-
board, we hope to motivate action across sectors (policy, insurance,
professional) to develop a comprehensive strategy to appropriately
address the needs of this challenging and neglected population.
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